First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
In the present editorial we describe the therapeutic achievements in the treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We focus on the major breakthroughs we have been witnessing in this context, from the introduction of crizotinib...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
BioExcel Publishing Ltd,
2018-07-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|